JP2023517312A5 - - Google Patents
Info
- Publication number
- JP2023517312A5 JP2023517312A5 JP2022553214A JP2022553214A JP2023517312A5 JP 2023517312 A5 JP2023517312 A5 JP 2023517312A5 JP 2022553214 A JP2022553214 A JP 2022553214A JP 2022553214 A JP2022553214 A JP 2022553214A JP 2023517312 A5 JP2023517312 A5 JP 2023517312A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062985946P | 2020-03-06 | 2020-03-06 | |
| US62/985,946 | 2020-03-06 | ||
| PCT/IB2021/051765 WO2021176367A1 (en) | 2020-03-06 | 2021-03-03 | Inhibitors of human immunodeficiency virus replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517312A JP2023517312A (ja) | 2023-04-25 |
| JPWO2021176367A5 JPWO2021176367A5 (https=) | 2024-03-13 |
| JP2023517312A5 true JP2023517312A5 (https=) | 2024-03-13 |
Family
ID=74870854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022553214A Pending JP2023517312A (ja) | 2020-03-06 | 2021-03-03 | ヒト免疫不全ウイルスの複製阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230106880A1 (https=) |
| EP (1) | EP4114527A1 (https=) |
| JP (1) | JP2023517312A (https=) |
| WO (1) | WO2021176367A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004593A (es) | 2018-10-24 | 2021-06-15 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| US12594276B2 (en) | 2024-02-05 | 2026-04-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| CA2897268C (en) | 2013-01-09 | 2018-12-04 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| CA2896244C (en) | 2013-01-09 | 2017-07-04 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
| TWI694071B (zh) * | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| EP3060554A1 (en) | 2013-10-24 | 2016-08-31 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| PT3186239T (pt) | 2014-08-29 | 2019-01-10 | Gilead Sciences Inc | Agentes antirretrovirais |
| US9855230B2 (en) | 2014-09-09 | 2018-01-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| TWI695003B (zh) * | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| BR112017022605A2 (pt) | 2015-04-23 | 2018-07-17 | Viiv Healthcare Uk No 5 Ltd | ?composto, composição, e, método para tratamento de infecção por hiv?. |
| CN107995910A (zh) | 2015-04-23 | 2018-05-04 | Viiv保健英国第五有限公司 | 人免疫缺陷病毒复制的抑制剂 |
| KR20230011471A (ko) | 2016-08-19 | 2023-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2019161280A1 (en) | 2018-02-16 | 2019-08-22 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| WO2019198024A1 (en) | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
-
2021
- 2021-03-03 JP JP2022553214A patent/JP2023517312A/ja active Pending
- 2021-03-03 US US17/801,410 patent/US20230106880A1/en active Pending
- 2021-03-03 EP EP21711369.5A patent/EP4114527A1/en not_active Withdrawn
- 2021-03-03 WO PCT/IB2021/051765 patent/WO2021176367A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025004088A1 (es) | Anticuerpos y fragmentos de unión al antígeno anti-glicoproteína de la espícula de sars-cov-2. | |
| JP2023517312A5 (https=) | ||
| CN306210643S (https=) | ||
| CN306347795S (https=) | ||
| CN305536710S (https=) | ||
| CN305536442S (https=) | ||
| CN305535004S (https=) | ||
| CN306180881S (https=) | ||
| CN305534697S (https=) | ||
| CN306181335S (https=) | ||
| CN306347328S (https=) | ||
| CN305533123S (https=) | ||
| CN305532218S (https=) | ||
| CN306317884S (https=) | ||
| CN305529587S (https=) | ||
| CN305528917S (https=) | ||
| CN306319679S (https=) | ||
| CN306182557S (https=) | ||
| CN306321745S (https=) | ||
| CN306186320S (https=) | ||
| CN306322003S (https=) | ||
| CN306188122S (https=) | ||
| CN305528412S (https=) | ||
| CN305527498S (https=) | ||
| CN306323666S (https=) |